Spectral Medical Provides Update on Tigris Clinical Trial
Robust recruitment activities experienced in closing weeks of September44 patients now enrolled
Follow this link:
Spectral Medical Provides Update on Tigris Clinical Trial
Author Archives: admin
Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange
POTOMAC, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (“Castellum”) (OTC: ONOV), a cybersecurity, electronic warfare, and IT services company, announced today that, subject to meeting all requirements (including the price requirement) at the time of listing, the Company’s application to list its shares of common stock (the “Common Stock”), has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering and a one-for-twenty reverse stock split of the Common Stock effective on or about October 7, 2022. The ticker symbol for the Common Stock will change to “CTM” upon listing. Trading of the Common Stock is expected to commence on or about October 7, 2022. The new CUSIP for the Common Stock following the reverse stock split will be 14838T204.
More:
Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange
Araris Biotech Closes $24 Million Financing Round
ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.
See the original post here:
Araris Biotech Closes $24 Million Financing Round
Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board
Follow this link:
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners
Walnut Creek, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView Capital Partners (“WestView”), a Boston-based growth equity firm, are pleased to jointly announce that WestView has completed a growth investment in DHC.
Here is the original post:
Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners
Transactions in connection with share buy-back program
Company announcement no. 16 - 224 October 2022
See the original post here:
Transactions in connection with share buy-back program
BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer
Industry veteran brings nearly 20 years of broad leadership experience in biopharma Industry veteran brings nearly 20 years of broad leadership experience in biopharma
See more here:
BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022.
See the original post here:
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
Company announcement – No. 43 / 2022
The rest is here:
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
Valneva Announces Closing of Upsized €102.9 Million Global Offering
Saint Herblain (France), October 4, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, announced today the closing of its previously announced global offering to specified categories of investors of an aggregate 21,000,000 new ordinary shares, consisting of a public offering of 375,000 American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States at an offering price of $9.51 per ADS (the “U.S. Offering”), and a concurrent private placement of 20,250,000 ordinary shares in Europe (including France) and other countries outside of the United States at the corresponding offering price of €4.90 per ordinary share (the “European Private Placement”, and, together with the U.S. Offering, the “Global Offering”). Aggregate gross proceeds of the Global Offering, before deducting underwriting commissions and estimated expenses payable by the Company, were approximately €102.9 million ($99.9 million).
The rest is here:
Valneva Announces Closing of Upsized €102.9 Million Global Offering